APA

Halsey, N. A., Coberly, J. S., Desormeaux, J., Atkinson, J., Moulton, L. H., Contave, M., Johnson, M., Davis, H., Geiter, L., Johnson, E., Huebner, R., Boulos, R., & Chaisson, R. E. (1998). Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet, 351(9105), 786. https://doi.org/10.1016/S0140-6736(97)06532-X

CHICAGO

Halsey, Neal A., Jacqueline S. Coberly, Julio Desormeaux, Joan Atkinson, Lawrence H. Moulton, Mireil Contave, Michael Johnson, et al. 1998. “Randomised Trial of Isoniazid versus Rifampicin and Pyrazinamide for Prevention of Tuberculosis in HIV-1 Infection.” Lancet 351 (9105): 786. doi:10.1016/S0140-6736(97)06532-X.

HARVARD

Halsey, N.A. et al. (1998) ‘Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection’, Lancet, 351(9105), p. 786. doi:10.1016/S0140-6736(97)06532-X.

MLA

Halsey, Neal A., et al. “Randomised Trial of Isoniazid versus Rifampicin and Pyrazinamide for Prevention of Tuberculosis in HIV-1 Infection.” Lancet, vol. 351, no. 9105, Mar. 1998, p. 786., https://doi.org/10.1016/S0140-6736(97)06532-X.

TURABIAN

Halsey, Neal A., Jacqueline S. Coberly, Julio Desormeaux, Joan Atkinson, Lawrence H. Moulton, Mireil Contave, Michael Johnson, et al. “Randomised Trial of Isoniazid versus Rifampicin and Pyrazinamide for Prevention of Tuberculosis in HIV-1 Infection.” Lancet 351, no. 9105 (March 14, 1998): 786. doi:10.1016/S0140-6736(97)06532-X.